Clinical Trial Update: Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) [Phase 2]

View source ↗

Summary

A Phase 2 trial of bafetinib for relapsed or refractory B-cell chronic lymphocytic leukemia conducted by CytRx has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Chronic Lymphocytic Leukemia

Drugs mentioned

• Bafetinib (INNO-406) (bafetinib)

Snippet

Sponsor: CytRx | Conditions: B-Cell Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED